Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [December 2017]

Product Code:
596200751
Publication Date:
December 2017
Format:
PDF
Price:
£910

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Boehringer Ingelheim’s November 2017 announcement that the European Commisssion had granted approval for the company’s adalimumab biosimilar, Cyltezo; the FDA’s acceptance of a regulatory submission for Sandoz’s rituximab biosimilar (GP2013), marketed in Europe as Rixathon/Riximyo since June 2017; and Celltrion’s development of a subcutaneous infliximab biosimilar.

Business Questions:

• How do KOLs perceive Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo?
• With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available?
• How do KOLs view Sandoz’s Rixathon, the second rituximab biosimilar to enter the RA space in Europe?
• Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product?
• What concerns might prescribers have regarding Celltrion’s subcutaneous infliximab biosimilar?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved